News | Prostate Cancer | April 24, 2017

Cancer Targeted Technology Highlights Prostate Cancer PET Imaging and Radiotherapeutic Advances

Company will share results of PSMA-targeted imaging and radiotherapeutic agents at numerous conferences from April-June

April 24, 2017 — Cancer Targeted Technology recently announced it is focusing on small molecules that target pivotal enzyme targets on cancer. CTT’s theranostic program is focused on the development of two drugs, CTT1057 and CTT1403, that respectively diagnose and treat prostate cancer based on targeting the biomarker prostate-specific membrane antigen (PSMA).

PSMA is over-expressed on prostate cancer, and this expression increases as the cancer metastasizes and becomes castrate-resistant. CTT’s phosphoramidate-based agents bind irreversibly to PSMA, and unlike other agents targeting PSMA, this distinctive mode of binding enhances uptake and internalization by tumor cells, leading to enhanced accumulation of the drugs within the tumor. Initial clinical data on CTT’s drugs in prostate cancer will be presented at five scientific and business meetings in April-June 2017.

CTT’s diagnostic positron emission tomography (PET) imaging agent, CTT1057, is radiolabeled with fluorine-18, and commenced clinical trials in patients with metastatic prostate cancer in Nov. 2016. The study is currently enrolling patients.

Upcoming presentations on the initial data from the CTT1057 clinical trial include:

  • American Society of Clinical Oncologists meeting in Chicago, June 2-6, 2017
    • “First-In-Human Phase 1 PET Study of CTT1057, a Novel 18F-Labeled Imaging Agent Targeting Prostate Specific Membrane Antigen (PSMA) in Prostate Cancer”
  • Society of Nuclear Medicine and Medical Imaging meeting in Denver, June 10-14, 2017.
    • “Comparison of a novel fluorine-18 labeled PSMA-targeting agent, CTT1057, to gallium-68 PSMA-11 in patients with prostate cancer”; and
    • “First-in-Human PET studies with CTT1057, a novel fluorine-18 labeled agent, targeting PSMA in prostate cancer”

CTT’s radiotherapeutic drug, CTT1403, is radiolabeled with lutetium-177, and is in late-stage preclinical development, with clinical trials planned for 2018. CTT1403 is uniquely designed to maximize tumor uptake, while minimizing side effects to normal tissues.

Presentations on CTT1403 radiotherapeutic agent include:

  • American Chemical Society meeting in San Francisco, April 2-6, 2017
    • “Improving the In Vitro and In Vivo Performance of a 177Lu-Labeled Phosphoramidate-Based PSMA Inhibitor with an Albumin-Binding Motif”; and
  • SNMMI 2017
    • “Comparison of traditional and albumin-binding Lu-177-labeled phosphoramidate-based PSMA inhibitors for targeted radionuclide therapy of prostate cancer”

For more information: www.cancertargetedtechnology.com

Related Content

Immune Inflammatory Levels Linked to Disease-Free Survival in Prostate Cancer
News | Prostate Cancer | November 19, 2018
Data from a validation study of a high-risk prostate cancer trial suggests that higher levels of pretreatment...
GE Healthcare Recalls Millennium Nuclear Medicine Systems
News | Nuclear Imaging | November 15, 2018
GE Healthcare announced it is recalling its Millennium Nuclear Medicine Systems due to an incident in which the the top...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...
MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine
News | Nuclear Imaging | November 07, 2018
With the recent announcement by Novartis to acquire Endocyte , interest from the conventional pharmaceutical industry...
Feature | PET Imaging | November 07, 2018 | By Greg Freiherr
Positron emission tomography (PET) is getting ready to venture outside oncology, cardiology and mainstream neurology....
Podcast | PET Imaging | November 07, 2018
PET is getting ready to venture outside oncology, cardiology and mainstream neurology.
A PET/CT head and neck cancer scan.

A PET/CT head and neck cancer scan.

Feature | Nuclear Imaging | November 05, 2018 | By Sabyasachi Ghosh
“Experimental validation implemented in real-life situations and not theoretical claims exaggerating small advantages